Light Chain Disorders Indicative of Immune Disorders and/or Cancers Associated with the COVID-19 Infections and Injections
DOI:
https://doi.org/10.56098/mmk5wh51Keywords:
cancers, COVID-19 vaccines, immune diseases, inflammation, kappa chains, lambda chains, serum free light chains, VAERSAbstract
Serum free light chain (sFLC) elevation following COVID-19 infection/illness and COVID-19 mRNA vaccination may indicate adverse immunological responses, such as clonal proliferation or inflammation. To evaluate the use of sFLC measurements, the Vaccine Adverse Event Reporting System (VAERS), maintained by the Centers for Disease Control and Prevention and the Food and Drug Administration, was diligently searched for sFLC abnormalities following COVID-19 vaccination.[1] Seventy-five cases were identified as having free light chain disorders following at least one injection of COVID-19 vaccine. Twenty-five cases (33%) were singled out that had complete quantitative data for serum kappa (sFLCk), serum lambda (sFLCλ), and the kappa/lambda ratio (sFLCR). Those 25 cases are in focus in this paper. Six patterns of sFLC elevations were identified. Case reports are given as examples. COVID-19 vaccines target lymphocytes to produce antibodies to neutralize the SARS-CoV-2 virus. Serum free light chain analysis provides insight into lymphocyte responses to mRNA including both polyclonal and monoclonal proliferation. Based on this study, careful evaluation of out-of-range values for sFLCk and/or sFLCλ is advisable even when sFLCR is within the normal range. FLC measurements should be further evaluated as a tool to guide clinical diagnosis and to monitor inflammatory and neoplastic (cancer) disease activity in persons affected by the COVID-19 injectables.
References
Aklaghi, K., Maclachlan, K., Korde, N., Mailankody, S., Lesokhin, A., Hassoun, H., Lu, S., Patel, D., Shah, U., Tan, C., Hultcrantz, M., Iyengar, N., Shah, G. L., Scordo, M., Lahoud, O. B., Chung, D. J., and Landau, H. J. (2025). Evaluating serum free light chain ratio as a biomarker in multiple myeloma. Haematologica, 110(1), 326–338. https://doi.org/10.3324/haematol.2024.285531
Aldén, M., Olofsson Falla, F., Yang, D., Barghouth, M., Luan, C., Rasmussen, M., & De Marinis, Y. (2022). Intracellular reverse transcription of Pfizer-BioNTech COVID-19 mRNA vaccine BNT162b2 in vitro in human liver cell line. Current issues in molecular biology, 44(3), 1115–1126. https://doi.org/10.3390/cimb44030073
Basile, U., La Rosa, G., Napodano, C., Pocino, K., Cappannoli, L., Gulli, F., Cianfrocca, C., Di Stasio, E., and Biasucci, L. M. (2019). Free light chains: A novel biomarker of cardiovascular disease. A pilot study. European Review for Medical and Pharmacological Sciences, 23(6), 2563–2569. https://doi.org/10.26355/eurrev_201903_17405
Baumeier, C., Aleshcheva, G., Harms, D., Gross, U., Hamm, C., Assmus, B., Westenfeld, R., Kelm, M., Rammos, S., Wenzel, P., Münzel, T., Elsässer, A., Gailani, M., Perings, C., Bourakkadi, A., Flesch, M., Kempf, T., Bauersachs, J., Escher, F., & Schultheiss, H. P. (2022). Intramyocardial Inflammation after COVID-19 Vaccination: An Endomyocardial Biopsy-Proven Case Series. International journal of molecular sciences, 23(13), 6940. https://doi.org/10.3390/ijms2313694
BioNTech Manufacturing GmbH, 01 July 2020. Report No. 38166 (LPT): Repeat-dose toxicity study of three LNP-formulated mRNA platforms encoding for viral proteins by repeated intramuscular administration. https://pdata0916.s3.us-east-2.amazonaws.com/pdocs/030123/125742_S1_M4_4.2.3.2+38166.pdf
BioNTech Manufacturing GmbH, & Pfizer Inc. (2021, February 8). BNT162b2—Module 2.4: Nonclinical overview [BLA STN 125742; FDA CBER submission]. PHMPT FOIA release. https://phmpt.org/wp-content/uploads/2022/03/125742_S1_M2_24_nonclinical-overview.pdf
Bird, J., Behrens, J., Westin, J., Turesson, I., Drayson, M., Beetham, R., D’Sa, S., Soutar, R., Waage, A., Gulbrandsen, N., Gregersen, H., and Low, E. (2009). UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): Guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). British Journal of Haematology, 147(1), 22–42. https://doi.org/10.1111/j.1365-2141.2009.07807.x
Bracco, F., Gallo, P., Menna, R., Battistin, L., and Tavolato, B. (1987). Free light chains in the CSF in multiple sclerosis. Journal of Neurology, 234(5), 303–307. https://doi.org/10.1007/BF00314285
Burkhardt, A., Lang, W., and Schwarz, N. (2024). Thorn in the flesh: How the corona vaccine-induced spike protein causes damage. Tredition.
Burkhardt, A. (2024). Autopsy-histology-study on vaccination-associated complications and deaths. In N. Wolf (Ed.), The Pfizer Papers (pp. 56–57). Skyhorse. https://www.skyhorsepublishing.com/9781648210372/the-pfizer-papers/
Burkhardt, A., & Lang, W. (2023). Burkhardt and Lang collection: Master documents [Unpublished manuscript].
Cassano, R., Ferraro, S., Stella, A., Buda, G., Orciuolo, E., and Petrini, M. (2025). Light chain deposition disease: Pathogenesis, clinical characteristics, and treatment strategies. Annals of Hematology, 104(7), 2083–2093. https://doi.org/10.1007/s00277-024-05911-9
Davids, M. S., Murali, M. R., and Kuter, D. J. (2010). Serum free light chain analysis. American Journal of Hematology, 85(10), 787–790. https://doi.org/10.1002/ajh.21815
Debord, M. (2025, June 18). Les vaccins ARNm COVID peuvent induire le cancer de 17 manières distinctes selon plus de 100 études [The mRNA COVID vaccines can cause cancer in 17 distinct ways according to more than 100 studies]. Le Point Critique. https://lepointcritique.fr/2025/06/19/vaccins-arnm-anti-covid-peuvent-induire-cancer-de-17-manieres-distinctes-selon-plus-de-100-etudes/
Demortiere, S., Marignier, R., Bertheaume, N., Vukusic, S., D’Hardivilliers, F., and Lebrun-Frenay, C. (2025). Diagnostic utility of kappa free light chain index in adults with inaugural optic neuritis. Neurology: Neuroimmunology and Neuroinflammation, 12(1), e200386. https://doi.org/10.1212/NXI.0000000000200386
Dispenzieri, A. (2019). POEMS syndrome: 2019 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 94(7), 812–827. https://doi.org/10.1002/ajh.25495
European Medicines Agency. (2020, December 21). Comirnaty: EPAR—Public assessment report (EMA/707383/2020; Corr. 2). https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf
European Medicines Agency. (2021, January). Spikevax (previously COVID-19 Vaccine Moderna): EPAR—Public assessment report (EMA/15689/2021). https://www.ema.europa.eu/en/documents/assessment-report/spikevax-previously-covid-19-vaccine-moderna-epar-public-assessment-report_en.pdf
Fend, F., Dogan, A., and Cook, J. R. (2023). Plasma cell neoplasms and related entities—evolution in diagnosis and classification. Virchows Archiv, 482(1), 163–177. https://doi.org/10.1007/s00428-022-03431-3
Gertz, M. A. (2024). Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment. American Journal of Hematology, 99(2), 309–324. https://doi.org/10.1002/ajh.27177
Emily R. Gordon, Oluwaseyi Adeuyan, Bradley D. Kwinta, Celine M. Schreidah, Lauren M. Fahmy, Dawn Queen, Megan H. Trager, Cynthia M. Magro, Larisa J. Geskin, Exploring Cutaneous Lymphoproliferative Disorders in the Wake of COVID-19 Vaccination, Skin Health and Disease, Volume 4, Issue 3, June 2024, ski2.367, https://doi.org/10.1002/ski2.367
Gudowska-Sawczuk, M., and Mroczko, B. (2023). Free light chains k and λ as new biomarkers of selected diseases. International Journal of Molecular Sciences, 24(11), 9531. https://doi.org/10.3390/ijms24119531
Gudowska-Sawczuk, M., Moniuszko-Malinowska, A., Pączek, S., Guziejko, K., Chorąży, M., and Mroczko, B. (2022). Evaluation of free light chains (FLCs) synthesis in response to exposure to SARS-CoV-2. International Journal of Molecular Sciences, 23(19), 11589. https://doi.org/10.3390/ijms231911589
Hegen, H., Arrambide, G., Gnanapavan, S., Kaplan, B., Khalil, M., Saadeh, R., Teunissen, C., Tumani, H., Villar, L. M., Willrich, M. A. V., and Zettl, U. K. (2022). Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement. Multiple Sclerosis Journal, 29(2), 182–195. https://doi.org/10.1177/13524585221134217
Hulscher, N. (2025, May 23). 17 ways mRNA shots may cause cancer, according to over 100 studies. https://www.thefocalpoints.com/p/17-ways-mrna-shots-may-cause-cancer
Huang, S., Wasifuddin, M., Bellamkonda, A., Lee, P. S., Chaudhry, M. R., & Wang, J. C. (2024). Light-Chain Myeloma Presented as Osseus Tumors: A Case Report. Journal of investigative medicine high impact case reports, 12, 23247096241307445. https://doi.org/10.1177/23247096241307445
Jenner, E. (2014). Serum free light chains in clinical laboratory diagnostics. Clinica Chimica Acta, 427, 15–20. https://doi.org/10.1016/j.cca.2013.08.018
Jones, H. B. (1848). On a new substance occurring in the urine of a patient with mollities ossium. Philosophical Transactions of the Royal Society, 138, 55–62. https://doi.org/10.1098/rstl.1848.0003
Kaplan, B., Livneh, A., & Sela, B. (2011). Immunoglobulin free light chain dimers in human diseases, The Scientific World Journal, 11, 901843https://doi.org/10.1100/tsw.2011.65
Katzmann, J. A., Clark, R., Abraham, R., Bryant, S., Lymp, S., Bradwell, A., and Kyle, R. (2002). Serum reference intervals and diagnostic ranges for free k and free λ immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains. Clinical Chemistry, 48(9), 1437–1444. https://doi.org/10.1093/clinchem/48.9.1437
Katzmann, J. A., Kyle, R. A., Benson, J., Larson, D. R., Snyder, M. R., Lust, J. A., Rajkumar, S. V., and Dispenzieri, A. (2009). Screening panels for detection of monoclonal gammopathies. Clinical Chemistry, 55(8), 1517–1522. https://doi.org/10.1373/clinchem.2009.126664
Krüger, U. and Lang, W. (2025). Vaccinated – dead: Histopathological findings following COVID-19 vaccination. Etica Media B.V. Swalman, Netherlands.
Krüger, U. (2024). Breast cancer specialist reveals increase in cancers and occurrences of ‘turbo cancers’ following genetic therapy vaccines. In N. Wolf et al. (Eds.), The Pfizer papers (pp. 127–138). Skyhorse Publishing. https://www.skyhorsepublishing.com/9781648210372/the-pfizer-papers/
Krumholz, H. M., Wu, Y., Sawano, M., Shah, R., Zhou, T., Arun, A. S., Khosla, P., Kaleem, S., Vashist, A., Bhattacharjee, B., Ding, Q., Lu, Y., Caraballo, C., Warner, F., Huang, C., Herrin, J., Putrino, D., Hertz, D., Dressen, B., and Iwasaki, A. (2023). Post-vaccination syndrome: A descriptive analysis of reported symptoms and patient experiences after COVID-19 immunization. Preprint (medRxiv). https://doi.org/10.1101/2023.11.09.23298266
Kyle, R. A., and Rajkumar, S. V. (2008). Multiple myeloma. Blood, 111(6), 2962–2972. https://doi.org/10.1182/blood-2007-10-078022
Kyle, R. A., Larson, D. R., Therneau, T. M., Dispenzieri, A., Kumar, S., Cerhan, J. R., and Rajkumar, S. V. (2018). Long-term follow-up of monoclonal gammopathy of undetermined significance. New England Journal of Medicine, 378(3), 241–249. https://doi.org/10.1056/NEJMoa1709974
Lan, M., Guo, Y., Wang, C., Wang, X., Li, J., and Wang, Y. (2024). Lambda light chain–restricted non-crystalline proximal tubulopathy with cast nephropathy in multiple myeloma: A case report and literature review. BMC Nephrology, 25(1), 325. https://doi.org/10.1186/s12882-024-03721-9
Lazarus, R., Klompas, M., and Bernstein, S. (2010). Electronic support for public health-vaccine adverse event reporting system (ESP:VAERS) (Grant Final Report). Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services. https://digital.ahrq.gov/sites/default/files/docs/publication/r18hs017045-lazarus-final-report-2011.pdf
Malecka-Gieldowska, M., Folta, M., Wisniewska, A., and Czyzewska, E. (2021). Cell population data and serum polyclonal immunoglobulin free light chains in the assessment of COVID-19 severity. Viruses, 13(7), 1381. https://doi.org/10.3390/v13071381
Marik, P., & Hope, J. (2025). COVID mRNA-induced “turbo cancers.” Journal of Independent Medicine, 1(3). https://10.71189/JIM/2025/V01N03A02
Martins, C., Gibier, J., Leroy, X., Bridoux, F., Touchard, G., Joly, D., Royal, V., Goujon, J. M., and Sirac, C. (2024). Non-myeloma light chain cast nephropathy: A multicenter retrospective study on clinicopathological characteristics. Haematologica, 109(8), 2557–2566. https://doi.org/10.3324/haematol.2024.285031
Matsumori, A., Shimada, T., Shimada, M., and Drayson, M. T. (2020). Immunoglobulin free light chains: An inflammatory biomarker of diabetes. Inflammation Research, 69(7), 715–718. https://doi.org/10.1007/s00011-020-01357-7
Mintoff, D., Scerri, L. and Betts, A. (2022), SARS-CoV-2 mRNA vaccine injection site pseudolymphoma. J Eur Acad Dermatol Venereol, 36: e20-e22. https://doi.org/10.1111/jdv.17680
Mundorf, A. K., Semmler, A., Heidecke, H., Schott, M., Steffen, F., Bittner, S., Lackner, K. J., Schulze-Bosse, K., Pawlitzki, M., Meuth, S. G., Klawonn, F., Ruhrländer, J., and Boege, F. (2024). Clinical and diagnostic features of post-acute COVID-19 vaccination syndrome (PACVS). Vaccines, 12(7), 790. https://doi.org/10.3390/vaccines12070790
Nakao, H., Koseki, T., Kato, K., Yamada, S., Tsuboi, N., Takahashi, K., and Mizuno, T. (2023). COVID-19 mRNA vaccination is associated with IgA nephropathy: An analysis of the Japanese adverse drug event report database. Journal of Pharmacy and Pharmaceutical Sciences, 26, 11453. https://doi.org/10.3389/jpps.2023.11453
Nance, K. D., & Meier, J. L. (2021). Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines. ACS Central Science, 7(5), 748–756. https://doi.org/10.1021/acscentsci.1c00197
Nushida, H., Ito, A., Kurata, H., Umemoto, H., Tokunaga, I., Iseki, H., & Nishimura, A. (2023). A case of fatal multi-organ inflammation following COVID-19 vaccination. Legal Medicine, 63, 102244. https://doi.org/10.1016/j.legalmed.2023.102244
Nyström, S., & Hammarström, P. (2022). Amyloidogenesis of SARS-CoV-2 spike protein. Journal of the American Chemical Society, 144(20), 8945–8950. https://doi.org/10.1021/jacs.2c03925
Park, K., and Kwon, S. (2024). Monoclonal gammopathy of renal significance from the perspective of nephrologists. Blood Research, 59(1), 28. https://doi.org/10.1007/s44313-024-00027-5
Pfizer, Inc. (2020). "A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Individuals." https://doi.org/10.2215/CJN.0000000000000400
Pfizer, Inc., and BioNTech SE. (2020). Pfizer-BioNTech COVID-19 vaccine (BNT162b2) VRBPAC briefing document. U.S. Food and Drug Administration. https://www.fda.gov/media/144245/download
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Jr., Hammitt, L. L., … Gruber, W. C. (2020). Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. The New England Journal of Medicine, 383(27), 2603–2615. https://doi.org/10.1056/NEJMoa2034577
Pratt, G., Pinney, J. H., & Cockwell, P. (2024). How I Treat Light Chain Cast Nephropathy. Clinical journal of the American Society of Nephrology : CJASN, 19(5), 650–652. https://doi.org/10.2215/CJN.0000000000000400
Rosati, M., Terpos, E., Homan, P., Bergamaschi, C., Karaliota, S., Ntanasis-Stathopoulos, I., Devasundaram, S., Bear, J., Burns, R., Bagratuni, T., Trougakos, I. P., Dimopoulos, M. A., Pavlakis, G. N., & Felber, B. K. (2023). Rapid transient and longer-lasting innate cytokine changes associated with adaptive immunity after repeated SARS-CoV-2 BNT162b2 mRNA vaccinations. Frontiers in Immunology, 14, Article 1292568. https://doi.org/10.3389/fimmu.2023.1292568
Röltgen, K., Nielsen, S., Silva, O., Pinsky, B. A., Nadeau, K. C., and Boyd, S. (2022). Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell, 185(6), 1025–1040. https://doi.org/10.1016/j.cell.2022.01.018
Salama, M. E. and Hoffman, R. (2023). Progress in the classification of hematopoietic and lymphoid neoplasms: Clinical implications. In R. Hoffman (Ed.), Hematology: Basic principles and practice (8th ed., pp. 800–812). Elsevier. https://doi.org/10.1016/B978-0-323-56738-1.00051-0
Samim, M., Dhar, D., Arshad, F., Anudeep, D. D. S., Patel, V. G., Neeharika, S. R., Dhamija, K., Ravindranath, C. M., Yadav, R., Raja, P., Netravathi, M., Menon, D., Holla, V. V., Kamble, N. L., Pal, P. K., Nalini, A., and Vengalil, S. (2023). Co-VAN study: COVID-19 vaccine associated neurological diseases—An experience from an apex neurosciences centre and review of the literature. Journal of Clinical Neuroscience, 108, 37–75. https://doi.org/10.1016/j.jocn.2022.12.015
Santiago, D., & Oller, J. W. (2023). Abnormal Clots and All-Cause Mortality During the Pandemic Experiment: Five Doses of COVID-19 Vaccine Are Evidently Lethal to Nearly All Medicare Participants. International Journal of Vaccine Theory, Practice, and Research, 3(1), 847–890. https://doi.org/10.56098/ijvtpr.v3i1.73
Semmler, A., Mundorf, A. K., Kuechler, A. S., Schulze-Bosse, K., Heidecke, H., Schulze-Forster, K., Schott, M., Uhrberg, M., Weinhold, S., and Lackner, K. J. (2023). Chronic fatigue and dysautonomia following COVID-19 vaccination is distinguished from normal vaccination response by altered blood markers. Vaccines, 11(11), 1642. https://doi.org/10.3390/vaccines11111642
Snozek, C. L. H., Kinard, T. N., & Adamski, J. (2018). Rapid reduction of extremely high kappa free light chains in a patient with myeloma cast nephropathy. Journal of clinical apheresis, 33(3), 439–443. https://doi.org/10.1002/jca.21619
Therapeutic Goods Administration. (2021, January 8). Non-clinical evaluation of BNT162b2 [mRNA] COVID-19 vaccine (Comirnaty) (FOI 2389, Document 6). https://www.tga.gov.au/sites/default/files/foi-2389-06.pdf
Thomas, S. J., Moreira, E. D., Jr., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., Bailey, R., Swanson, K. A., Xu, X., Roychoudhury, S., Koury, K., Bouguermouh, S., Kalina, W. V., Cooper, D., Frenck, R. W., Jr., … Jansen, K. U. (2021). Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. The New England Journal of Medicine, 385(19), 1761–1773. https://doi.org/10.1056/NEJMoa2110345
US Food and Drug Administration. (2021). Summary basis for regulatory action – Comirnaty (BNT162b2 (COVID-19 vaccine, mRNA)): Clinical review (BLA 125742/0). https://doi.org/10.1056/NEJMoa2110345
Verdaguer-Faja, J., Valdivieso, L., Fabregat-Pratdepadua, M., Melendo, G. T., Quer, A., Carrascosap, J. M., & Boada, A. (2024). Cutaneous Pseudolymphoma after COVID-19 Vaccine Injection. Indian journal of dermatology, 69(3), 269–272. https://doi.org/10.4103/ijd.ijd_420_22
Vudathaneni, V. K. P., Nadella, S. B., Hema, D., and Boyapati, R. (2023). Renal complications following COVID-19 vaccination: A narrative literature review. Indian Journal of Community Medicine: Official Publication of Indian Association of Preventive and Social Medicine, 48(2), 214–219. https://doi.org/10.4103/ijcm.ijcm_654_22
Walsh, E. E., Frenck, R. W., Jr., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., and Bailey, R. (2020). Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. New England Journal of Medicine, 383(24), 2439–2450. https://doi.org/10.1056/NEJMoa2027906
Xu, K., Kamuriwo, L., Anderson, C., & Jasani, P. (2022). IgG kappa multiple myeloma with isolated central nervous system relapse. EJHaem, 3(3), 1082–1083. https://doi.org/10.1002/jha2.469
Zamfir, M. A., Moraru, L., Dobrea, C., Scheau, A. E., Iacob, S., Moldovan, C., Scheau, C., Caruntu, C., & Caruntu, A. (2022). Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases. Medicina (Kaunas, Lithuania), 58(7), 874. https://doi.org/10.3390/medicina58070874
Zhao, L., Jin, S., Wang, S., Zhang, Z., Wang, X., Chen, Z., Wang, X., Huang, S., Zhang, D., & Wu, H. (2024). Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances. Signal transduction and targeted therapy, 9(1), 225. https://doi.org/10.1038/s41392-024-01947-5
Zhu, L., Hu, Q., Zhang, L., and Li, A. (2024). The role of minimal residual disease and serum free light chain ratio in the management of multiple myeloma. Discover Oncology, 15(1), 229. https://doi.org/10.1007/s12672-024-01090-1
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Robert W. Chandler
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The copyright for materials in this journal, IJVTPR, is owned by the author. The author, however, grants first right of publication to the journal, IJVTPR and assures the editorial staff of the journal that the work submitted has not simultaneously been submitted to any other journal, nor is it under consideration for publication by any other journal. If any portion of the work submitted has appeared elsewhere, the quoted material is properly cited and credit is given to the original publisher. The submitting author (or the principal and corresponding author of the work) also assures the editors of IJVTPR that he or she has obtained all required written permissions from any quoted authors or publishers of quoted materials. The submitting author also agrees to hold IJVTPR and its editorial staff harmless from any infractions of copyright law that may be discovered at any time in the future in the submitted work. The author assures the editorial staff at IJVTPR that none of the work submitted is plagiarized, and that any recycled or precycled material by the author is identified as such with proper credits in the text to any other parties holding a copyright interest in the quoted material.